" class="no-js "lang="en-US"> Richard Glynn - Medtech Alert
Wednesday, August 06, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Richard Glynn

Richard Glynn

About Richard Glynn

Prior to founding 87%, Richard was CEO of Ladbrokes, and CEO and then Chairman of Sporting Index. He used to serve as a Special Trustee of Great Ormond Street Hospital Children’s Charity for 10 years.

Related Story

Fundraising

 Wellbeing Platform 87% Raises £1.6million in Funding in Just Two Weeks | Pharmtech Focus

Wellbeing Platform 87% Raises £1.6million in Funding in Just Two Weeks

August 4 2021

Leading workplace wellbeing platform 87% has raised £1.6 million in seed funding to accelerate its […]